Comparison · NCT02275780-sae
Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg: serious adverse events. Trial comparisons, record NCT02275780-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02275780-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.117 | 0.089 | 0.154 | wilson | |
| Risk in group 2 | 0.128 | 0.0981 | 0.165 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0104 | -0.0573 | 0.0364 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.918 | 0.629 | 1.34 | log | |
| Odds ratio, group 1 over group 2 | 0.907 | 0.589 | 1.4 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Doravirine 100 mg than on Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg | 95.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Doravirine 100 mg | Double-blind Doravirine 100 mg administered p.o. q.d. + investigator-selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants continued in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants continued to receive the Doravirine regimen in Study Extension 2 for an additional 96 weeks, and in Study Extension 3 for an additional 96 weeks. | 45 | 383 | EG000 |
| Group 2 | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg | Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants continued in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator-selected TRUVADA™ or EPZICOM™/ KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants continued to receive the Doravirine regimen in Study Extension 2 for an additional 96 weeks, and in Study Extension 3 for an additional 96 weeks. | 49 | 383 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Week 386
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
- NCT number
- NCT02275780
- Phases
- PHASE3
- Conditions
- HIV-1
- Interventions
- Doravirine, Darunavir, Ritonavir, TRUVADA™ or EPZICOM™/KIVEXA™
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2018-10-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02275780?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02275780-sae